代谢工程改造黑曲霉生产葡萄糖二酸

葡萄糖二酸是葡萄糖的一种二元羧酸衍生物,是重要的平台化合物,被应用于医药、化工等领域。本研究以黑曲霉为底盘细胞,通过表达来自恶臭假单胞菌Pseudomonas putida KT2440的糖醛酸脱氢酶基因ppudh,成功在黑曲霉中实现了葡萄糖二酸的合成,产量为18.74 mg/L;在此基础上通过共过表达黑曲霉自身来源的肌醇加氧酶(anmioxA)和肌醇-1-磷酸合酶(aninoA)、酿酒酵母Saccharomyces cerevisiae S288C来源的羧酸转运蛋白(scJEN1),强化了合成通路和外泌途径,将产量提高至102.10 mg/L;通过表达来自乳酸乳球菌Lactococcus lactis subsp.cremoris MG1363的NADH氧化酶(llnox),建立NAD⁺辅因子循环系统,使产量进一步提高至115.65 mg/L;利用RNA干扰技术对竞争支路中的关键酶磷酸果糖激酶(pfkA)和葡萄糖-6-磷酸脱氢酶(zwf)进行弱化表达,葡萄糖二酸最终的产量达到313.65 mg/L。本研究为微生物高效生产葡萄糖二酸和下游相关产品生产奠定基础。     

构建酿酒酵母细胞工厂高效合成摩尔酸

[目的] 摩尔酸作为齐墩果烷型三萜化合物具有抗HIV、抗炎等多种生物学活性,其前体物质是计曼尼醇,本研究基于合成生物学策略构建酿酒酵母细胞工厂高效合成摩尔酸。[方法] 运用CRISPR/Cas9技术,首先分别整合不同来源的氧化鲨烯环化酶（OSCs）,筛选高产计曼尼醇底盘细胞;进一步异源表达长春花来源的细胞色素P450氧化酶（CYP716AL1）和麻风树来源的细胞色素P450还原酶（JcCPR）,构建摩尔酸生物合成途径;并通过CYP716AL1和不同来源的CPR适配研究以及过表达甲羟戊酸（MVA）代谢途径中关键酶的方式提高摩尔酸的产量。[结果] 整合苹果来源的氧化鲨烯环化酶MdOSC获得的重组菌株计曼尼醇产量最高,达68.3 mg/L;以此为底盘细胞进一步整合CYP716AL1和JcCPR实现了摩尔酸的生物合成,产量为15.0 mg/L;共表达CYP716AL1和拟南芥来源的CPR获得的重组菌株摩尔酸产量最高,达到24.3 mg/L;最后过表达MVA代谢途径中的关键酶法呢基焦磷酸合酶（ERG20）和鲨烯环氧酶（ERG1）,获得的重组菌株摩尔酸产量高达34.1 mg/L。[结论] 本研究实现了摩尔酸的高效生物合成,为构建高产齐墩果烷型三萜酿酒酵母细胞工厂提供了理论和技术依据。     

产肌醇酿酒酵母基因工程菌的构建

【目的】过表达酿酒酵母肌醇合成关键酶基因INO1,促进肌醇合成,构建能够分泌肌醇的基因工程菌株。【方法】构建r DNA介导的INO1基因多拷贝整合表达载体p URIH,电转化酿酒酵母Y01菌株,构建工程菌株YI2-1和YI2-2,荧光定量PCR方法分析INO1基因表达量。敲除Kan MX抗性基因,HPLC检测重组菌发酵液中肌醇含量。【结果】获得INO1基因过表达菌株YI2-1和YI2-2,YI2-1的INO1基因表达量是出发菌Y01的16.235倍。敲除Kan MX抗性基因的菌株命名为YI2-1△KP,初步检测YI2-1△KP产肌醇量为627 mg/L。【结论】r DNA介导的INO1基因多拷贝整合表达载体p URIH能够有效地过表达目的基因;过表达菌株合成的肌醇不仅能满足自身的需要,而且能够向胞外分泌,具有潜在的工业应用价值。     

强化类球红细菌辅因子NADPH再生以提高法尼醇的产量

法尼醇(Farnesol,FOH)是由焦磷酸异戊烯基(IPP)和焦磷酸二甲基烯丙基(DMAPP)合成的法尼酰基焦磷酸盐(FPP)去焦磷酸化作用生成的。在类球红细菌中IPP和DMAPP是由MEP途径生成,而完整的MEP途径需要消耗大量的辅因子NADPH,增加胞内NADPH的量有可能强化FOH的合成。文中从增加NADPH的生成和降低NADPH的消耗这两个策略出发,分别干扰了编码6-磷酸葡萄糖异构酶基因(pgi)和谷氨酸脱氢酶基因(gdhA)的表达,同时强化了磷酸戊糖途径中6-葡萄糖磷酸脱氢酶基因(zwf)和6-葡萄糖酸磷酸脱氢酶基因(gnd)的表达。实验结果表明,经改造的菌株NADPH含量显著增加,干扰菌株中菌株RSpgii的产量较高,为3.91 mg/g,在过表达的菌株中同时过表达zwf和gnd基因的重组菌株(RSzg)的FOH产量提高到了3.43 mg/g。为了获得FOH产量更高的菌株,以RSpgii为出发菌株,分别与zwf和gnd组合调控,获得的菌株RSzgpi的产量达到了最高量为4.48 mg/g,是出发菌株RS-GY2产率的2.24倍。     

代谢工程改造酿酒酵母合成肌醇

【目的】肌醇别名环己六醇,是一种具有生物活性的糖醇,在医药、食品和饲料等领域具有重要的应用价值。为获得生产肌醇的微生物细胞工厂,通过代谢工程改造,构建生产肌醇的酿酒酵母工程菌株。【方法】对酿酒酵母肌醇合成途径的正负调控同时改造,过表达肌醇-3-磷酸合成酶基因ino1,敲除肌醇生物合成的转录抑制子基因opi1和抗性基因kan MX,获得重组菌。利用气相色谱法检测重组菌发酵液中肌醇含量。【结果】构建了生物安全性的产肌醇基因工程菌株,摇瓶培养产量为1.021 g/L。【结论】通过过表达ino1和敲除opi1来改造酿酒酵母,能够有效提高重组菌的肌醇产量,为下一步的微生物发酵法产肌醇的工业应用奠定基础。     

代谢工程改造酿酒酵母合成柠檬烯及其衍生物

柠檬烯及其衍生物紫苏酸作为重要的生物活性天然产物，广泛应用于食品、化妆品、保健品和医药等行业。然而，低效率的植物提取与高能耗的化工合成限制了柠檬烯和紫苏酸的工业合成。本研究在酿酒酵母中通过过氧化物酶体区室化表达绿薄荷来源的柠檬烯合酶，构建获得重组菌株，柠檬烯产量为0.038 mg/L。采用模块化工程分步表达参与柠檬烯合成的基因ERG10、ERG13、tHMGR、ERG12、ERG8、IDI1、MVD1、ERG20ww以及tLS，以研究其对柠檬烯产量的影响。通过增加前体模块，柠檬烯产量增加至1.14 mg/L。采用高拷贝数的质粒表达上述关键基因，柠檬烯的产量显著提高，达到86.74 mg/L，提高至初始菌株产量的4 337倍。以构建的柠檬烯生产菌株为出发菌株，通过表达丹参来源的细胞色素P450酶基因，实现了紫苏酸的生成，其产量达4.42 mg/L，为利用酿酒酵母构建高产单萜类天然产物的细胞工厂奠定了基础。     

产肌醇毕赤酵母细胞工厂的优化

【背景】肌醇是一种B族维生素,广泛应用于食品、医药、饲料等领域。微生物发酵法是最具前景的肌醇生产方法,但使用大肠杆菌生产的肌醇在食品及医药领域中的使用受到限制。毕赤酵母作为生物安全菌株是工业上生产异源蛋白的良好宿主,其本身含有天然的肌醇合成途径,具有被改造成为高效生产肌醇细胞工厂的潜力。【目的】通过代谢工程改造毕赤酵母工程菌株,降低副产物的生成并提高肌醇的产量。【方法】以实验室前期构建的产肌醇毕赤酵母工程菌株为出发菌株,确定副产物阿拉伯糖醇、核糖醇和甘露糖合成相关基因。通过关键基因敲除、发酵液中葡萄糖浓度控制降低副产物的产量。通过过表达甘油转运蛋白、甘油激酶和甘油-3-磷酸脱氢酶基因实现产肌醇毕赤酵母对甘油和葡萄糖的共利用,得到重组菌Z10。经过发酵条件优化,进一步提高Z10的肌醇产量。【结果】在最优条件下,重组菌Z10的肌醇产量达到36.7 g/L,是目前酵母类细胞工厂生产肌醇的最高值,副产物总产量与出发菌株相比降低了63.1%。【结论】在毕赤酵母中建立了降低阿拉伯糖醇、核糖醇和甘露糖合成的有效策略,并通过甘油、葡萄糖共利用及相对应的发酵条件优化提高了肌醇产量,为肌醇及其他高价值生物...     

氨甲酰磷酸不同合成途径在大肠杆菌中的比较

【背景】氨甲酰磷酸是生物合成代谢中精氨酸与嘧啶的重要前体物质,在工业微生物生产精氨酸与嘧啶及其衍生物中发挥关键作用。【目的】在大肠杆菌Escherichia coli BW25113中比较氨甲酰磷酸不同合成途径的催化效率。【方法】在大肠杆菌Escherichia coli BW25113中过表达鸟氨酸氨甲酰基转移酶(OTC)的基础上,分别过表达大肠杆菌自身的氨基甲酸激酶(CK)和氨甲酰磷酸合酶(CPSⅡ)并表征其反应效果。通过优化底物供应(调整底物浓度与引入L-谷氨酰胺合成酶)对CK与CPSⅡ的催化反应进行优化。【结果】在大肠杆菌中过表达OTC,建立细胞水平氨甲酰磷酸检测体系。在此基础上比较不同来源的CK,发现大肠杆菌来源的CK效果最好,50mmol/LNH4HCO3条件下全细胞催化9h得到2.95±0.15mmol/LL-瓜氨酸;过表达CPSⅡ时,50mmol/LL-谷氨酰胺催化9h得到3.16±0.29 mmol/L L-瓜氨酸。通过改变底物NH4HCO3浓度和引入外源L-谷氨酰胺合成酶(GS)等方式对CK与CPSⅡ的催化反应分别进行优化后,100 mmol/L NH4HCO3条件下,L-瓜氨酸浓度分别提高至4.67±0.55mmol/L和6.12±0.38mmol/L,且过表达GS后CPSⅡ途径可以利用NH3,不需要额外添加L-谷氨酰胺。【结论】引入L-谷氨酰胺合成酶后的CPSⅡ途径合成氨甲酰磷酸的能力优于CK途径,为精氨酸、嘧啶及其衍生物的合成提供了一种更加高效的策略。     

细胞膜合成途径模块化调控与形态改造提高大肠杆菌β-胡萝卜素的积累与产量

β-胡萝卜素是类胡萝卜素家族中的典型代表,属于疏水性较强的化合物,前期研究表明,改变细胞膜形态以及增加3-磷酸甘油二酯的供给,均可容纳更多的β-胡萝卜素,从而提高其产量。然而在之前的研究中,没有对细胞膜的磷脂中主要组分磷脂酰乙醇胺的合成途径对β-胡萝卜素积累的影响进行系统的讨论。本研究将磷脂酰乙醇胺的合成途径分为上中下游3个模块,对它们的多种表达组合策略进行比较。首先过表达了上游模块1,菌株CAR016的β-胡萝卜素的产量与单位细胞的β-胡萝卜素产量均有显著提高,分别可达到44 mg/L以及13.7 mg/g DCW。与对照菌株相比,分别提高30.5%与35.6%。过表达磷脂酰乙醇胺合成的中游模块,β-胡萝卜素的产量以及单位细胞的β-胡萝卜素的产量分别为103.5 mg/L DCW与19.8 mg/g DCW。与对照菌株CAR016(pACYC184-M)相比,分别提高1.4倍与53.5%。将上游模块1与中游模块2共表达,菌株CAR016(pModule1,pModule2)单位细胞的β-胡萝卜素产量为22.3 mg/g DCW。与CAR016(pModule2)相比,单位细胞产量提高18%,与出发菌株CAR016(pTrc99A-M,pACYC184-M)相比,单位细胞的β-胡萝卜素产量提高122%。本研究找到了磷脂酰乙醇胺合成途径表达的最优组合策略,可以产生更大量的细胞膜,为储存β-胡萝卜素提供了更多的空间,从而进一步提高β-胡萝卜素的产量。细胞膜形态和合成途径的模块化改造,是今后提高类胡萝卜素产量的新方向。     

植物戊糖磷酸途径及其两个关键酶的研究进展

戊糖磷酸途径是植物体中糖代谢的重要途径,主要生理功能是产生供还原性生物合成需要的NADPH,可供核酸代谢的磷酸戊糖以及一些中间产物可参与氨基酸合成和脂肪酸合成等.葡萄糖-6-磷酸脱氢酶和6-磷酸葡萄糖酸脱氢酶是戊糖磷酸途径的两个关键酶,广泛的分布于高等植物的胞质和质体中.本文综述了植物戊糖磷酸途径及其两个关键酶的分子生物学的研究进展,讨论了该途径在植物生长发育和环境胁迫应答中的作用.     

Production of glucaric acid from myo-inositol in engineered Pichia pastoris

A potential myo-inositol oxygenase (ppMIOX) was identified as a functional enzyme and a glucaric acid synthetic pathway was firstly constructed in Pichia pastoris. Coexpression of the native ppMIOX and the urinate dehydrogenase (Udh) from Pseudomonas putida KT2440 led to obvious accumulation of glucaric acid (90.46 ± 0.04 mg/L) from myo-inositol whereas no glucaric acid was detected from glucose. In comparison, coexpression of the heterologous mouse MIOX (mMIOX) and Udh resulted in higher titers of glucaric acid from glucose and myo-inositol, 107.19 ± 11.91 mg/L and 785.4 ± 1.41 mg/L, respectively. By applying a fusion expression strategy with flexible peptides, the mMIOX specific activity and the glucaric acid concentration were significantly increased. Using glucose and myo-inositol as carbon substrates, the production of glucaric acid was substantially enhanced to 6.61 ± 0.30 g/L in fed-batch cultures. To the best of our knowledge, this is the highest reported value to date.     

高效合成葡萄糖二酸酿酒酵母工程菌的构建

葡萄糖二酸是天然存在的一种重要二元酸,其在医疗保健和化工工业等领域具有很高的实际应用价值,因此被称为"最具价值的生物炼制产品之一".以酿酒酵母(Saccharomyces cerevisiae)为底盘微生物,文中考察了过量表达肌醇转运蛋白Itr1、融合表达肌醇加氧酶和葡萄糖醛酸脱氢酶以及弱化表达葡萄糖6-磷酸脱氢酶基因...     

A novel framework for the cell-free enzymatic production of glucaric acid

Glucaric acid (GlucA) is a valuable glucose-derived chemical with promising applications as a biodegradable and biocompatible chemical in the manufacturing of plastics, detergents and drugs. Recently, there has been a significant focus on producing GlucA microbially (in vivo) from renewable materials such as glucose, sucrose and myo-inositol. However, these in vivo GlucA production processes generally lack efficiency due to toxicity problems, metabolite competition and suboptimal enzyme ratios. Synthetic biology and accompanying cell-free biocatalysis have been proposed as a viable approach to overcome many of these limitations. However, cell-free biocatalysis faces its own limitations for industrial applications due to high enzyme costs and cofactor consumption. We have constructed a cell-free GlucA pathway and demonstrated a novel framework to overcome limitations of cell-free biocatalysis by i) the combination of both thermostable and mesophilic enzymes, ii) incorporation of a cofactor regeneration system and iii) immobilisation and recycling of the pathway enzymes. The cell-free production of GlucA was achieved from glucose-1-phosphate with a titre of 14.1 ± 0.9 mM (3.0 ± 0.2 g l⁻¹) and a molar yield of 35.2 ± 2.3% using non-immobilised enzymes, and a titre of 8.1 ± 0.2 mM (1.70 ± 0.04 g l⁻¹) and a molar yield of 20.2 ± 0.5% using immobilised enzymes with a total reaction time of 10 h. The resulting productivities (0.30 ± 0.02 g/h/l for free enzymes and 0.170 ± 0.004 g/h/l for immobilised enzymes) are the highest productivities so far reported for glucaric acid production using a synthetic enzyme pathway.     

CipA-mediating enzyme self-assembly to enhance the biosynthesis of pyrogallol in Escherichia coli

Pyrogallol is a valuable phenolic compound and displays various physiological and pharmaceutical functions. Chemical synthesis of pyrogallol suffered from many issues, including environmental pollution, high cost, and low yield. Here, to address the above drawbacks, an artificial pathway for de novo pyrogallol production was established and this pathway only needed two exogenous enzymes (Y385F/T294A PobA and 3,4-dihydroxybenzoic acid decarboxylase (PDC)). Y385F/T294A PobA is a mutant of PobA which is a hydroxylase from Pseudomonas aeruginosa, while PDC is a decarboxylase from Klebsiella pneumoniae subsp. pneumoniae. First, the conversion efficiency of PDC was tested and 1800 ± 100 mg/L pyrogallol was generated from 4 g/L gallic acid (GA). Subsequently, assembly of the whole pathway enabled 33 ± 6 mg/L pyrogallol production from simple carbon sources. After that, based on the assembling property of CipA (a hydrophobic protein) and to enhance the hydroxylation of 3,4-dihydroxybenzoic acid, CipA was employed to organize its fusion (Y385F/T294A PobA) into protein crystalline inclusions (PCIs). Remarkably, the formation of CipA-Y385F/T294A PobA PCIs increased the pyrogallol production to 60 ± 6 mg/L, a 1.8 ± 0.4-fold higher value as compared to the strain without enzyme self-assembly. Additionally, the titer of pyrogallol was enhanced to 80 ± 1 mg/L through yeast extract concentration optimization. This work not only realizes the biosynthesis of pyrogallol from renewable carbon sources but also demonstrates that using CipA-mediating enzyme self-assembly could reinforce the hydroxylation efficiency of Y385F/T294A PobA, resulting in the enhancement of pyrogallol production.

     

Production of Glucaric Acid from a Synthetic Pathway in Recombinant Escherichia coli

A synthetic pathway has been constructed for the production of glucuronic and glucaric acids from glucose in Escherichia coli. Coexpression of the genes encoding myo-inositol-1-phosphate synthase (Ino1) from Saccharomyces cerevisiae and myo-inositol oxygenase (MIOX) from mice led to production of glucuronic acid through the intermediate myo-inositol. Glucuronic acid concentrations up to 0.3 g/liter were measured in the culture broth. The activity of MIOX was rate limiting, resulting in the accumulation of both myo-inositol and glucuronic acid as final products, in approximately equal concentrations. Inclusion of a third enzyme, uronate dehydrogenase (Udh) from Pseudomonas syringae, facilitated the conversion of glucuronic acid to glucaric acid. The activity of this recombinant enzyme was more than 2 orders of magnitude higher than that of Ino1 and MIOX and increased overall flux through the pathway such that glucaric acid concentrations in excess of 1 g/liter were observed. This represents a novel microbial system for the biological production of glucaric acid, a “top value-added chemical” from biomass.     

Engineering the oleaginous yeast Yarrowia lipolytica for high-level resveratrol production

Resveratrol is a plant secondary metabolite with multiple health-beneficial properties. Microbial production of resveratrol in model microorganisms requires extensive engineering to reach commercially viable levels. Here, we explored the potential of the non-conventional yeast Yarrowia lipolytica to produce resveratrol and several other shikimate pathway-derived metabolites (p-coumaric acid, cis,cis-muconic acid, and salicylic acid). The Y. lipolytica strain expressing a heterologous pathway produced 52.1 ± 1.2 mg/L resveratrol in a small-scale cultivation. The titer increased to 409.0 ± 1.2 mg/L when the strain was further engineered with feedback-insensitive alleles of the key genes in the shikimate pathway and with five additional copies of the heterologous biosynthetic genes. In controlled fed-batch bioreactor, the strain produced 12.4 ± 0.3 g/L resveratrol, the highest reported titer to date for de novo resveratrol production, with a yield on glucose of 54.4 ± 1.6 mg/g and a productivity of 0.14 ± 0.01 g/L/h. The study showed that Y. lipolytica is an attractive host organism for the production of resveratrol and possibly other shikimate-pathway derived metabolites.     

Porting the synthetic D‐glucaric acid pathway from Escherichia coli to Saccharomyces cerevisiae

D‐Glucaric acid can be produced as a value‐added chemical from biomass through a de novo pathway in Escherichia coli. However, previous studies have identified pH‐mediated toxicity at product concentrations of 5 g/L and have also found the eukaryotic myo‐inositol oxygenase (MIOX) enzyme to be rate‐limiting. We ported this pathway to Saccaromyces cerevisiae, which is naturally acid‐tolerant and evaluate a codon‐optimized MIOX homologue. We constructed two engineered yeast strains that were distinguished solely by their MIOX gene – either the previous version from Mus musculus or a homologue from Arabidopsis thaliana codon‐optimized for expression in S. cerevisiae – in order to identify the rate‐limiting steps for D‐glucaric acid production both from a fermentative and non‐fermentative carbon source. myo‐Inositol availability was found to be rate‐limiting from glucose in both strains and demonstrated to be dependent on growth rate, whereas the previously used M. musculus MIOX activity was found to be rate‐limiting from glycerol. Maximum titers were 0.56 g/L from glucose in batch mode, 0.98 g/L from glucose in fed‐batch mode, and 1.6 g/L from glucose supplemented with myo‐inositol. Future work focusing on the MIOX enzyme, the interplay between growth and production modes, and promoting aerobic respiration should further improve this pathway.     

Engineering precursor supply for the high-level production of ergothioneine in Saccharomyces cerevisiae

Ergothioneine (ERG) is an unusual sulfur-containing amino acid. It is a potent antioxidant, which shows great potential for ameliorating neurodegenerative and cardiovascular diseases. L-ergothioneine is rare in nature, with mushrooms being the primary dietary source. The chemical synthesis process is complex and expensive. Alternatively, ERG can be produced by fermentation of recombinant microorganisms engineered for ERG overproduction. Here, we describe the engineering of S. cerevisiae for high-level ergothioneine production on minimal medium with glucose as the only carbon source. To this end, metabolic engineering targets in different layers of the amino acid metabolism were selected based on literature and tested. Out of 28 targets, nine were found to improve ERG production significantly by 10%–51%. These targets were then sequentially implemented to generate an ergothioneine-overproducing yeast strain capable of producing 106.2 ± 2.6 mg/L ERG in small-scale cultivations. Transporter engineering identified that the native Aqr1 transporter was capable of increasing the ERG production in a yeast strain with two copies of the ERG biosynthesis pathway, but not in the strain that was further engineered for improved precursor supply. Medium optimization indicated that additional supplementation of pantothenate improved the strain's productivity further and that no supplementation of amino acid precursors was necessary. Finally, the engineered strain produced 2.39 ± 0.08 g/L ERG in 160 h (productivity of 14.95 ± 0.49 mg/L/h) in a controlled fed-batch fermentation without supplementation of amino acids. This study paves the way for the low-cost fermentation-based production of ergothioneine.     

Engineering Saccharomyces cerevisiae for isoprenol production

Isoprenol (3-methyl-3-butene-1-ol) is a valuable drop-in biofuel and an important precursor of several commodity chemicals. Synthetic microbial systems using the heterologous mevalonate pathway have recently been developed for the production of isoprenol in Escherichia coli, and a significant yield and titer improvement has been achieved through a decade of research. Saccharomyces cerevisiae has been widely used in the biotechnology industry for isoprenoid production, but there has been no good example of isoprenol production reported in this host. In this study, we engineered the budding yeast S. cerevisiae for improved biosynthesis of isoprenol. The strain engineered with the mevalonate pathway achieved isoprenol production at the titer of 36.02 ± 0.92 mg/L in the flask. The IPP (isopentenyl diphosphate)-bypass pathway, which has shown more efficient isoprenol production by avoiding the accumulation of the toxic intermediate in E. coli, was also constructed in S. cerevisiae and improved the isoprenol titer by 2-fold. We further engineered the strains by deleting a promiscuous endogenous kinase that could divert the pathway flux away from the isoprenol production and improved the titer to 130.52 ± 8.01 mg/L. Finally, we identified a pathway bottleneck using metabolomics analysis and overexpressed a promiscuous alkaline phosphatase to relieve this bottleneck. The combined efforts resulted in the titer improvement to 383.1 ± 31.62 mg/L in the flask. This is the highest isoprenol titer up to date in S. cerevisiae and this work provides the key strategies to engineer yeast as an industrial platform for isoprenol production.     

Metabolic engineering of Escherichia coli for the production of benzoic acid from glucose

Benzoic acid (BA) is an important platform aromatic compound in chemical industry and is widely used as food preservatives in its salt forms. Yet, current manufacture of BA is dependent on petrochemical processes under harsh conditions. Here we report the de novo production of BA from glucose using metabolically engineered Escherichia coli strains harboring a plant-like β-oxidation pathway or a newly designed synthetic pathway. First, three different natural BA biosynthetic pathways originated from plants and one synthetically designed pathway were systemically assessed for BA production from glucose by in silico flux response analyses. The selected plant-like β-oxidation pathway and the synthetic pathway were separately established in E. coli by expressing the genes encoding the necessary enzymes and screened heterologous enzymes under optimal plasmid configurations. BA production was further optimized by applying several metabolic engineering strategies to the engineered E. coli strains harboring each metabolic pathway, which included enhancement of the precursor availability, removal of competitive reactions, transporter engineering, and reduction of byproduct formation. Lastly, fed-batch fermentations of the final engineered strain harboring the β-oxidation pathway and the strain harboring the synthetic pathway were conducted, which resulted in the production of 2.37 ± 0.02 g/L and 181.0 ± 5.8 mg/L of BA from glucose, respectively; the former being the highest titer reported by microbial fermentation. The metabolic engineering strategies developed here will be useful for the production of related aromatics of high industrial interest.